**PATENT** 

# In re application of: Chau, Vincent Application No.: 10/681,690 Group No.: 1652 Filed: October 8, 2003 Examiner: Fronda, Christian L.

NEDD-8 CONJUGATING ENZYME 1 AND METHODS OF USE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

For:

Date: \_\_\_\_November 2, 2006

#### TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

## IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

- The information disclosure statement submitted herewith is being filed:

   ( ) Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).
  - OR
  - M After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but before the mailing date of either:
    - (1) a final action under Section 1.113,

#### CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

#### MAILING

X	deposited with the United States Postal Service in an envel	lope addressed to Mail Stop Amendment, Commissioner for
	Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
	37 C.F.R. SECTION 1.8(a)	37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Mailing Label No

as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office (571-273,8300).

Signature

Sean Hunziker/Beverly Sotiropoulos

(type or print name of person certifying)

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

#### Practitioner's Docket No. MPI97-057P1RCP1CN1M

- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

- Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).
- () Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).
- () No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

#### **FEE PAYMENT**

- 2. (x) The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).
  - (x) Applicant believes no fee is due in connection with this submission.

Fee due	\$180.00	

#### METHOD OF PAYMENT OF FEE

3.	()	Attached is a check in the amount of \$	·	
	(X)	Charge Account No. 501668 in the amount of	\$180.00	
	<b>(X)</b>	A duplicate of this request is attached.		_

If any additional fees are due, please charge Account 501668.

November 2, 2006

MILLENNIUM PHARMACEUTICALS, INC.

Tracy M. Soussat, Ph.D. Registration No. 50,609

40 Landsdowne Street Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617 551 8820

NOV 0 7 2006 Practitioner's Jocket No. MP197-057P1RCP1CN1M

**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Chau, Vincent		
Application No.:	10/681,690	Group No.:	1652
Filed:	October 8, 2003	Examiner:	Fronda, Christian L.
For:	NEDD-8 CONJUGATING ENZYN	Æ 1 AND ME	ETHODS OF USE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

#### List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

- 1. (x) Preliminary Statements;
- 2. (x) Forms PTO/SB/08A (1 page) (substitute for Form PTO-1449);
- 3. (x) Copy of Listed Information Item Accompanying This Statement

#### **Preliminary statements**

#### CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

#### **MAILING**

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

#### 37 C.F.R. SECTION 1.8(a)

#### 37 C.F.R. SECTION 1.10\*

	` '			
×	with sufficient postage as first class mail.		as "Express Mail Post Office to Addressee" Mailing Label No.	
	T transmitted by facsimile to the Patent and Trad	RANSMISSION	•	10581553
Date:	November 2, 2006	Signatui	CE SCELEES AND PORT	
Date	110 YCHIOCI 2, 2000	Signatui	Sean Hunziker/Beverly Sonropoulos	

(type or print name of person certifying)

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

#### Practitioner's Docket No. MPI97-057P1RCP1CN1M

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

#### Copies of Listed Information Items Accompanying This Statement

Legible copies of relevant portions of item B1 listed in Form PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

November 2, 2006

MILLENNIUM PHARMACEUTICALS, INC.

Tracy M. Sionssat, Ph.D.

Registration No. 50,609

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617 551 8820

PTC	)/SB/08A	(10-9
 10/01/00	OHID OC	- 4 00

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

rwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/99. OMB 0654-0031

etate ioi ioiiii	144570110			
	TION	DISCI	000	ID

Please upe a plus sign (+) inside this box

Sheet

### ORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of

Complete if Known					
Application Number	10/681,690				
Filing Date	October 8, 2003				
First Named Inventor	Chau, Vincent				
Group Art Unit	1652				
Examiner Name	Fronda, Christian L.				
Attorney Docket Number	MPI97-057P1RCP1CN1M				

U.S. PATENT DOCUMENTS						
		U.S. Pate	nt Document		Date of Publication of	Pages, Columns, Lines, Where
Examiner	Cite		Kind Code <sup>2</sup>		Cited Document	Relevant Passages or Relevant
Initials*	No.1	Number	(if known)	of Cited Document	(MM-DD-YYYY)	Figures Appear
	ļ		_			
	ļ					
		ļ				
	l					
			<del></del>			
			<del></del>			
		<u> </u>		<u> </u>	· · · · · · · · · · · · · · · · · · ·	
	_	<u> </u>	-			
					• • • • • • • • • • • • • • • • • • • •	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Fo Office <sup>3</sup>	reign Patent Do	ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	WO	95/18974	A2	Mitotix, Inc.	07/13/1995 & 08/17/1995	Entire document	

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.